In 2022, our laboratory identified upregulation of the FAK homologue proline‐rich tyrosine kinase 2 (PYK2) in malignant B cells from CLL patients compared to healthy B cells. This evidence concerns the gene PTK2B and B-cell chronic lymphocytic leukemia.